APA (7th ed.) Citation

SC, O., HJ, v. d. H., LP, K., K, S., MB, O., EN, v. d. B., . . . ECW, B. (2020). DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies. Blood cancer journal, 10(3), 30. https://doi.org/10.1038/s41408-020-0292-7

Chicago Style (17th ed.) Citation

SC, Oostindie, et al. "DuoHexaBody-CD37®, a Novel Biparatopic CD37 Antibody with Enhanced Fc-mediated Hexamerization as a Potential Therapy for B-cell Malignancies." Blood Cancer Journal 10, no. 3 (2020): 30. https://doi.org/10.1038/s41408-020-0292-7.

MLA (9th ed.) Citation

SC, Oostindie, et al. "DuoHexaBody-CD37®, a Novel Biparatopic CD37 Antibody with Enhanced Fc-mediated Hexamerization as a Potential Therapy for B-cell Malignancies." Blood Cancer Journal, vol. 10, no. 3, 2020, p. 30, https://doi.org/10.1038/s41408-020-0292-7.